Article: Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus
Emerging infectious diseases, 25(10):1878-1883
2019
Abstract: Middle East respiratory syndrome coronavirus (MERS-CoV) was detected in humans in 2012. Since then, sporadic outbreaks with primary transmission through dromedary camels to humans and outbreaks in healthcare settings have shown that MERS-CoV continues to ...
Institution | Charité - Universitätsmedizin Berlin Deutsches Zentrum für Infektionsforschung |
---|---|
Abstract | Middle East respiratory syndrome coronavirus (MERS-CoV) was detected in humans in 2012. Since then, sporadic outbreaks with primary transmission through dromedary camels to humans and outbreaks in healthcare settings have shown that MERS-CoV continues to pose a threat to human health. Several serologic assays for MERS-CoV have been developed globally. We describe a collaborative study to investigate the comparability of serologic assays for MERS-CoV and assess any benefit associated with the introduction of a standard reference reagent for MERS-CoV serology. Our study findings indicate that, when possible, laboratories should use a testing algorithm including >2 tests to ensure correct diagnosis of MERS-CoV. We also demonstrate that the use of a reference reagent greatly improves the agreement between assays, enabling more consistent and therefore more meaningful comparisons between results. |
Keywords | COVID-19 ; Coronavirus ; Oman ; MERS-CoV ; Middle East respiratory syndrome coronavirus ; South Korea ; Saudi Arabia ; antibodies ; diagnostics ; serology ; standard ; viruses |
Language | English |
Document type | Article |
Database | Repository for Life Sciences |
Full text online
More links
Kategorien
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.